Non-small Cell Lung Cancer
Conditions
Keywords
Next Generation Sequencing
Brief summary
To study and comprehend the evolutionary and genomic landscape between primary and metastatic sites and the dynamics of intratumour and intertumour heterogeneity over time with reference to the treatment modalities for each Chinese patient with non-small cell lung cancer.
Detailed description
The importance of intratumour and intertumour heterogeneity in non-small cell lung cancer has been extensively interrogated recently. However there is a lack of similar data associated with treatment and survival outcomes in Chinese population. Unicorn-Quest, a prospective observational study of Chinese patients with either primary or metastatic non-small cell lung cancer, aims to identify the evolutionary changes from the primary tumour, regional nodes and distant metastases of the same patients and among different patients, through multiregion and longitudinal tumour and nodal collection with next-generation sequencing. By following non-small cell lung cancer from early stage to relapse or distant metastasis, identifying the changes of genomic landscape with correlation with treatment and survival outcomes, this study may help identify unique cancer trajectories and novel therapeutic targets for non-small cell lung cancer in Chinese population.
Interventions
GENETICNext generation sequencing
Next generation sequencing
Sponsors
Queen Mary Hospital, Hong Kong
Queen Elizabeth Hospital, Hong Kong
Pamela Youde Nethersole Eastern Hospital
Prince of Wales Hospital, Shatin, Hong Kong
Princess Margaret Hospital, Hong Kong
Tuen Mun Hospital
United Christian Hospital
The University of Hong Kong
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Written Informed consent * Patients ≥18 years of age, with histologically confirmed non-squamous non-small cell lung cancer who plan to receive active anti-cancer treatment for their non-small cell lung cancer. * Sufficient tissues with a minimum of two tumour or nodal regions are available for the study based on pre-operative imaging and post-operative pathological findings.
Exclusion criteria
* Any other\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy). Any other\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\*\*. \*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer \*\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC. * Psychological condition that would preclude informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intratumour heterogeneity | 5 years | Number of participants who have single actionable and non-actionable genetic mutations and multiple actionable and non-actionable genetic mutations within the same groups of patients with early and metastatic non-small cell lung cancer |
| Intertumour heterogeneity | 5 years | Number of participants who have single actionable and non-actionable genetic mutations and multiple actionable and non-actionable genetic mutations of different groups of patients with early and metastatic non-small cell lung cancer |
Countries
Hong Kong
Outcome results
None listed